BRAF and colorectal carcinoma: A BRAF mutation is diagnosed in approximately 5%–15% of all CRC tumours and is considered a prognostic biomarker of less favourable outcome in the general population of CRC patients overall but also in dMMR subgroup—both in the early stage [30] and advanced disease [31].